Meeting
2012 ASCO Annual Meeting
Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts).
Authors
Sophie Cousin
Centre Oscar Lambret, Lille, France
Sophie Cousin , Jean-Yves Blay , François Bertucci , Nicolas Isambert , Antoine Italiano , Emmanuelle Bompas , Isabelle Ray-Coquard , Delphine Perrot , Binh Bui Nguyen , Marie Chaix , Loic Chaigneau , Nadege Corradini , Nicolas Penel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 30, 2012 (suppl; abstr 10014)
DOI
10.1200/jco.2012.30.15_suppl.10014
Abstract #
10014
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
First Author: Roberta Sanfilippo
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2014 ASCO Annual Meeting
Predictive value of BRCA1 haplotype for trabectedin efficacy in patients with advanced soft-tissue sarcoma.
First Author: Audrey Laroche
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon